Endo Trial Cabergoline Modest Igf1 Mild

---
name: endo-trial-cabergoline-modest-igf1-mild
description: Suggests a trial of a dopamine agonist, usually cabergoline, as initial adjuvant therapy in patients with only modest IGF-1 elevations and mild GH excess symptoms after surgery. Use when postoperative IGF-1 is mildly elevated and symptoms of GH excess are mild.
---

# Trial of cabergoline as initial adjuvant therapy for modest disease

## STEP 1 — Gather Information
Confirm postoperative status (typically ≥12 weeks after transsphenoidal surgery). Measure serum IGF-1 (age‑adjusted) and random GH. Assess for mild GH‑excess symptoms (e.g., fatigue, headache, mild sweating) and absence of severe features (visual field defects, cardiomegaly, pronounced acral changes).

## STEP 2 — Rule In / Rule Out
Rule in modest disease if IGF-1 is ≤1.5× ULN and GH is <1.0 µg/L with only mild symptoms. Rule out if IGF-1 >1.5× ULN, GH ≥1.0 µg/L, or moderate‑to‑severe symptoms (significant sweating, arthralgias, sleep apnea, cardiomyopathy) — proceed to SRL or pegvisomant per 5.2.

## STEP 3 — Classify or Stratify
Classify as “modest biochemical disease” when criteria above are met. Stratify further by prolactin level: if mildly elevated, cabergoline may address both GH and prolactin; if normal, cabergoline still appropriate as dopamine agonist trial.

## STEP 4 — Decide
Initiate cabergoline at a low dose (e.g., 0.5 mg twice weekly) and titrate based on tolerance and response. Schedule IGF-1 and symptom assessment at 12 weeks; if IGF-1 normalizes or improves ≥20% and symptoms improve, continue; otherwise escalate to SRL or pegvisomant per 5.2/5.7.

## Clinical Guardrails / Mimics / Pitfalls
Do not use cabergoline as monotherapy for moderate‑to‑severe disease; avoid high doses (>2 mg/week) without cardiac valve surveillance due to valvulopathy risk. Do not initiate in pregnancy without obstetric counseling. Ensure IGF-1 assay consistency; do not rely on random GH alone for efficacy assessment.

## Concrete Clinical Example
A 48‑year‑old woman undergoes transsphenoidal resection for a macroadenoma. Twelve weeks post‑op IGF-1 is 1.3× ULN, random GH 0.6 µg/L, she reports mild intermittent headaches and fatigue, no visual field deficits. Cabergoline 0.5 mg twice weekly is started. At 12 weeks IGF-1 falls to 1.0× ULN and headaches improve; therapy is continued with monitoring every 6 months.

**Source:** Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700